Industry News: The Future of Cancer Therapeutics: Accelerating Progress at the Molecular Level

05 Sep 2011

Join the industry professionals in attendance at the Old Royal Naval College - Greenwich, London, UK on the 11th-12th October 2011 for a chance to discuss the latest trends and developments in Cancer Research. New independent evidence confirms that the increasing global trend of unhealthy and sedentary lifestyles is responsible for putting millions at an unnecessarily high risk of cancer.

New estimates released by the World Cancer Research Fund (WCRF) global network suggest that across a range of countries, making lifestyle changes including maintaining a healthy weight, eating a healthy diet and taking regular physical activity can reduce the risk of common cancers by up to a third.

These findings are further supported by the World Health Organization’s (WHO) new Global Recommendations on Physical Activity for Health. This landmark report reinforces that regular physical activity has the potential to prevent many diseases such as breast and colon cancers, cardiovascular diseases and diabetes.

With an opportuntity to network with senior level executives from the top 20 pharmaceutical and biotechnology industries, the summit will focus on The Future of Cancer Therapeutics: Accelerating Progress at the Molecular Level. Hear updates from industry analysts on 'The Implementation of New Technologies & Novel Agents', 'Why Label Free Biomolecular Analysis for Drug Discovery could be beneficial' and 'Key for future breakthroughs'. Scientific presentations will provide in-depth coverage of developing adoptive cellular therapy for Cancer, with sessions dedicated to pre-clinical models and early stage trials of engineered T cells.

The conference will focus on main areas of:

1) Future of cancer therapeutics: implementing new technologies & novel agents
2) Cancer stem cells
3) Combining molecularly targeted therapies & chemoradiation
4) Inflammation and cancer
5) Molecular and cellular mechanisms of oncogenesis & tumor suppression
6) Public policy issues, ethics & confidentiality